Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 113

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Tolerance and Persistence of Pseudomonas aeruginosa in Biofilms Exposed to Antibiotics: Molecular Mechanisms, Antibiotic Strategies and Therapeutic Perspectives

Soares, Anaïs, Alexandre, Kévin, Etienne, Manuel · 2020 · Frontiers in Microbiology

Abstract

Pseudomonas aeruginosa biofilm-related infections are difficult to treat with antibiotics. Along the different layers of the biofilm, the P. aeruginosa population is heterogeneous, exhibiting an extreme ability to adapt his metabolic activity to the local microenvironment. At the deepest layers of the biofilm is a subset of dormant cells, called persister cells. Though antimicrobial failure might be multifactorial, it is now demonstrated that these persister cells, genetically identical to a fully susceptible strain, but phenotypically divergent, are highly tolerant to antibiotics, and contribute to antimicrobial failure. By eradicating susceptible, metabolically active cells, antibiotics bring out pre-existing persister cells. The biofilm mode of growth creates microenvironment conditions that activate stringent response mechanisms, SOS response and toxin-antitoxin systems that render the bacterial population highly tolerant to antibiotics. Using diverse, not standardized, models of biofilm infection, a large panel of antibiotic regimen has been evaluated. They demonstrated that biofilm growth had an unequal impact of antibiotic activity, colistin and meropenem being the less impacted antibiotics. Different combination and sequential antimicrobial therapies were also evaluated, and could be partially efficient, but none succeeded in eradicating persister cells, so that non-antibiotic alternative strategies are currently under development. This article reviews the molecular mechanisms involved in antibiotic tolerance and persistence in P. aeruginosa biofilm infections. A review of the antimicrobial regimen evaluated for the treatment of P. aeruginosa biofilm infection is also presented. While tremendous progress has been made in the understanding of biofilm-related infections, alternative non-antibiotic strategies are now urgently needed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fmicb.2020.02057

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 71

  1. Allison, 2011, Heterogeneous bacterial persisters and engineering approaches to eliminate them., Curr. Opin. Microbiol., 14, 593, 10.1016/j.mib.2011.09.002 · DOI · Paper page
  2. Baek, 2020, Effect of colistin-based antibiotic combinations on the eradication of persister cells in Pseudomonas aeruginosa., J. Antimicrob. Chemother., 75, 917, 10.1093/jac/dkz552 · DOI
  3. Bernier, 2013, Starvation, together with the SOS response, mediates high biofilm-specific tolerance to the fluoroquinolone ofloxacin., PLoS Genet., 9, 10.1371/journal.pgen.1003144 · DOI · Paper page
  4. Biswas, 2012, Colistin: an update on the antibiotic of the 21st century., Expert Rev. Anti Infect. Ther., 10, 917, 10.1586/eri.12.78 · DOI · Paper page
  5. Bjarnsholt, 2005, Pseudomonas aeruginosa tolerance to tobramycin, hydrogen peroxide and polymorphonuclear leukocytes is quorum-sensing dependent., Microbiol. Read. Engl., 151, 373, 10.1099/mic.0.27463-0 · DOI · Paper page
  6. Borriello, 2004, Oxygen limitation contributes to antibiotic tolerance of Pseudomonas aeruginosa in Biofilms., Antimicrob. Agents Chemother., 48, 2659, 10.1128/AAC.48.7.2659-2664.2004 · DOI · Paper page
  7. Brackman, 2011, Quorum sensing inhibitors increase the susceptibility of bacterial biofilms to antibiotics In Vitro and In Vivo., Antimicrob. Agents Chemother., 55, 2655, 10.1128/AAC.00045-11 · DOI · Paper page
  8. Brauner, 2016, Distinguishing between resistance, tolerance and persistence to antibiotic treatment., Nat. Rev. Microbiol., 14, 320, 10.1038/nrmicro.2016.34 · DOI · Paper page
  9. Cao, 2015, Antibiotic penetration and bacterial killing in a Pseudomonas aeruginosa biofilm model., J. Antimicrob. Chemother, 70, 2057, 10.1093/jac/dkv058 · DOI
  10. Chung, 2019, Eradication of persister cells of Acinetobacter baumannii through combination of colistin and amikacin antibiotics., J. Antimicrob. Chemother., 74, 1277, 10.1093/jac/dkz034 · DOI
  11. Ciofu, 2017, Antibiotic treatment of biofilm infections., APMIS, 125, 304, 10.1111/apm.12673 · DOI · Paper page
  12. Ciofu, 2019, Tolerance and resistance of Pseudomonas aeruginosa Biofilms to antimicrobial agents-how P. aeruginosa can escape antibiotics., Front. Microbiol., 10, 10.3389/fmicb.2019.00913 · DOI · Paper page
  13. Costerton, 1999, Bacterial biofilms: a common cause of persistent infections., Science, 284, 1318, 10.1126/science.284.5418.1318 · DOI · Paper page
  14. De Groote, 2009, Novel persistence genes in Pseudomonas aeruginosa identified by high-throughput screening., FEMS Microbiol. Lett., 297, 73, 10.1111/j.1574-6968.2009.01657.x · DOI
  15. de la Fuente-Núñez, 2014, Broad-spectrum anti-biofilm peptide that targets a cellular stress response., PLoS Pathog., 10, 10.1371/journal.ppat.1004152 · DOI · Paper page
  16. Del Pozo, 2018, Biofilm-related disease., Expert Rev. Anti Infect. Ther., 16, 51, 10.1080/14787210.2018.1417036 · DOI · Paper page
  17. Díez-Aguilar, 2015, Antimicrobial activity of fosfomycin-tobramycin combination against Pseudomonas aeruginosa Isolates assessed by time-kill assays and mutant prevention concentrations., Antimicrob. Agents Chemother., 59, 6039, 10.1128/AAC.00822-15 · DOI
  18. Dörr, 2009, SOS response induces persistence to fluoroquinolones in Escherichia coli., PLoS Genet., 5, 10.1371/journal.pgen.1000760 · DOI · Paper page
  19. Dörr, 2010, Ciprofloxacin causes persister formation by inducing the TisB toxin in Escherichia coli., PLoS Biol., 8, 10.1371/journal.pbio.1000317 · DOI · Paper page
  20. Fernández-Barat, 2017, Phenotypic shift in Pseudomonas aeruginosa populations from cystic fibrosis lungs after 2-week antipseudomonal treatment., J. Cyst. Fibros., 16, 222, 10.1016/j.jcf.2016.08.005 · doi:10.1016/j.jcf.2016.08.005
  21. Fernández-Olmos, 2012, In vitro prevention of Pseudomonas aeruginosa early biofilm formation with antibiotics used in cystic fibrosis patients., Int. J. Antimicrob. Agents, 40, 173, 10.1016/j.ijantimicag.2012.04.006 · doi:10.1016/j.ijantimicag.2012.04.006
  22. Gómez-Junyent, 2019, Efficacy of ceftolozane/tazobactam, alone and in combination with colistin, against multidrug-resistant Pseudomonas aeruginosa in an in vitro biofilm pharmacodynamic model., Int. J. Antimicrob. Agents, 53, 612, 10.1016/j.ijantimicag.2019.01.010 · DOI
  23. Haagensen, 2017, Spatiotemporal pharmacodynamics of meropenem- and tobramycin-treated Pseudomonas aeruginosa biofilms., J. Antimicrob. Chemother., 72, 3357, 10.1093/jac/dkx288 · DOI
  24. Hall, 2017, Molecular mechanisms of biofilm-based antibiotic resistance and tolerance in pathogenic bacteria., FEMS Microbiol. Rev., 41, 276, 10.1093/femsre/fux010 · DOI · Paper page
  25. Harms, 2016, Mechanisms of bacterial persistence during stress and antibiotic exposure., Science, 354, 10.1126/science.aaf4268 · DOI · Paper page
  26. Hauryliuk, 2015, Recent functional insights into the role of (p)ppGpp in bacterial physiology., Nat. Rev. Microbiol., 13, 298, 10.1038/nrmicro3448 · DOI · Paper page
  27. Hazan, 2016, Auto poisoning of the respiratory chain by a quorum-sensing-regulated molecule favors biofilm formation and antibiotic tolerance., Curr. Biol., 26, 195, 10.1016/j.cub.2015.11.056 · DOI · Paper page
  28. Hengzhuang, 2013, High β-Lactamase levels change the pharmacodynamics of β-Lactam antibiotics in Pseudomonas aeruginosa biofilms., Antimicrob. Agents Chemother., 57, 196, 10.1128/AAC.01393-12 · DOI
  29. Hengzhuang, 2011, Pharmacokinetics/pharmacodynamics of colistin and imipenem on mucoid and nonmucoid Pseudomonas aeruginosa biofilms., Antimicrob. Agents Chemother., 55, 4469, 10.1128/AAC.00126-11 · DOI · Paper page
  30. Hengzhuang, 2012, In Vivo pharmacokinetics/pharmacodynamics of colistin and imipenem in Pseudomonas aeruginosa biofilm infection., Antimicrob. Agents Chemother., 56, 2683, 10.1128/AAC.06486-11 · DOI · Paper page
  31. Kamble, 2020, Antibiotic tolerance in biofilm and stationary-phase planktonic cells of Staphylococcus aureus., Microb. Drug Resist., 10.1089/mdr.2019.0425 · DOI
  32. Keren, 2004, Specialized persister cells and the mechanism of multidrug tolerance in Escherichia coli., J. Bacteriol., 186, 8172, 10.1128/JB.186.24.8172-8180.2004 · DOI · Paper page
  33. Khakimova, 2013, The stringent response controls catalases in Pseudomonas aeruginosa and is required for hydrogen peroxide and antibiotic tolerance., J. Bacteriol., 195, 2011, 10.1128/JB.02061-12 · DOI · Paper page
  34. Klockgether, 2013, Intraclonal diversity of the Pseudomonas aeruginosa cystic fibrosis airway isolates TBCF10839 and TBCF121838: distinct signatures of transcriptome, proteome, metabolome, adherence and pathogenicity despite an almost identical genome sequence: genome and phenome diversity of P. aeruginosa clone TB., Environ. Microbiol., 15, 191, 10.1111/j.1462-2920.2012.02842.x · doi:10.1111/j.1462-2920.2012.02842.x
  35. Koo, 2017, Targeting microbial biofilms: current and prospective therapeutic strategies., Nat. Rev. Microbiol., 15, 740, 10.1038/nrmicro.2017.99 · DOI · Paper page
  36. Lebeaux, 2013, From in vitro to in vivo models of bacterial biofilm-related infections., Pathogens, 2, 288, 10.3390/pathogens2020288 · DOI · Paper page
  37. Lebeaux, 2014, Biofilm-related infections: bridging the gap between clinical management and fundamental aspects of recalcitrance toward antibiotics., Microbiol. Mol. Biol. Rev., 78, 510, 10.1128/MMBR.00013-14 · DOI · Paper page
  38. Lenz, 2008, Localized gene expression in Pseudomonas aeruginosa biofilms., Appl. Environ. Microbiol., 74, 4463, 10.1128/AEM.00710-08 · DOI · Paper page
  39. Li, 2016, HigB of Pseudomonas aeruginosa Enhances killing of phagocytes by up-regulating the Type III secretion system in ciprofloxacin induced persister cells., Front. Cell. Infect. Microbiol., 6, 10.3389/fcimb.2016.00125 · DOI · Paper page
  40. Lora-Tamayo, 2014, Activity of colistin combined with doripenem at clinically relevant concentrations against multidrug-resistant Pseudomonas aeruginosa in an in vitro dynamic biofilm model., J. Antimicrob. Chemother., 69, 2434, 10.1093/jac/dku151 · DOI
  41. Lutz, 2012, Macrolides decrease the minimal inhibitory concentration of anti-pseudomonal agents against Pseudomonas aeruginosa from cystic fibrosis patients in biofilm., BMC Microbiol., 12, 10.1186/1471-2180-12-196 · DOI
  42. Macià, 2011, Dynamics of mutator and antibiotic-resistant populations in a pharmacokinetic/pharmacodynamic model of Pseudomonas aeruginosa biofilm treatment., Antimicrob. Agents Chemother., 55, 5230, 10.1128/AAC.00617-11 · DOI
  43. Macia, 2014, Antimicrobial susceptibility testing in biofilm-growing bacteria., Clin. Microbiol. Infect., 20, 981, 10.1111/1469-0691.12651 · DOI · Paper page
  44. Marchaim, 2019, Use of colistin in critically Ill patients., Adv. Exp. Med. Biol., 1145, 155, 10.1007/978-3-030-16373-0_12 · DOI
  45. Mensa, 2018, Antibiotic selection in the treatment of acute invasive infections by Pseudomonas aeruginosa: guidelines by the Spanish society of chemotherapy., Rev. Espanola Quimioter. Publ. Soc. Espanola Quimioter., 31, 78
  46. Michiels, 2016, In Vitro emergence of high persistence upon periodic aminoglycoside challenge in the ESKAPE pathogens., Antimicrob. Agents Chemother., 60, 4630, 10.1128/AAC.00757-16 · DOI
  47. Murakami, 2005, Role for rpoS gene of Pseudomonas aeruginosa in antibiotic tolerance., FEMS Microbiol. Lett., 242, 161, 10.1016/j.femsle.2004.11.005 · doi:10.1016/j.femsle.2004.11.005
  48. Nalca, 2006, Quorum-sensing antagonistic activities of azithromycin in Pseudomonas aeruginosa PAO1: a global approach., Antimicrob. Agents Chemother., 50, 1680, 10.1128/AAC.50.5.1680-1688.2006 · DOI · Paper page
  49. Nguyen, 2011, Active starvation responses mediate antibiotic tolerance in biofilms and nutrient-limited bacteria., Science, 334, 982, 10.1126/science.1211037 · DOI · Paper page
  50. Olivares, 2020, Clinical impact of antibiotics for the Treatment of Pseudomonas aeruginosa biofilm infections., Front. Microbiol., 10, 10.3389/fmicb.2019.02894 · DOI · Paper page
  51. Pamp, 2008, Tolerance to the antimicrobial peptide colistin in Pseudomonas aeruginosa biofilms is linked to metabolically active cells, and depends on the pmr and mexAB-oprM genes., Mol. Microbiol., 68, 223, 10.1111/j.1365-2958.2008.06152.x · DOI · Paper page
  52. Pang, 2019, Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies., Biotechnol. Adv., 37, 177, 10.1016/j.biotechadv.2018.11.013 · DOI · Paper page
  53. Peyrusson, 2020, Intracellular Staphylococcus aureus persisters upon antibiotic exposure., Nat. Commun., 11, 10.1038/s41467-020-15966-7 · DOI · Paper page
  54. Pletzer, 2016, Anti-biofilm peptides as a new weapon in antimicrobial warfare., Curr. Opin. Microbiol., 33, 35, 10.1016/j.mib.2016.05.016 · DOI · Paper page
  55. Reffuveille, 2014, A broad-spectrum antibiofilm peptide enhances antibiotic action against bacterial biofilms., Antimicrob. Agents Chemother., 58, 5363, 10.1128/AAC.03163-14 · DOI · Paper page
  56. Rojo-Molinero, 2016, Sequential treatment of biofilms with aztreonam and tobramycin is a novel strategy for combating Pseudomonas aeruginosa chronic respiratory infections., Antimicrob. Agents Chemother., 60, 2912, 10.1128/AAC.00196-16 · doi:10.1128/aac.00196-16
  57. Roy, 2018, Strategies for combating bacterial biofilms: a focus on anti-biofilm agents and their mechanisms of action., Virulence, 9, 522, 10.1080/21505594.2017.1313372 · DOI · Paper page
  58. Ruddy, 2013, Sputum tobramycin concentrations in cystic fibrosis patients with repeated administration of inhaled tobramycin., J. Aerosol. Med. Pulm. Drug Deliv., 26, 69, 10.1089/jamp.2011.0942 · DOI
  59. Schumacher, 2015, HipBA-promoter structures reveal the basis of heritable multidrug tolerance., Nature, 524, 59, 10.1038/nature14662 · DOI · Paper page
  60. Smith, 2006, Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients., Proc. Natl. Acad. Sci. U.S.A., 103, 8487, 10.1073/pnas.0602138103 · DOI · Paper page
  61. Soares, Efficacy of a ciprofloxacin/amikacin combination against planktonic and biofilm cultures of susceptible and low-level resistant Pseudomonas aeruginosa., J. Antimicrob. Chemother., 74, 3252, 10.1093/jac/dkz355 · DOI
  62. Soares, Understanding ciprofloxacin failure in pseudomonas aeruginosa biofilm: persister cells survive matrix disruption., Front. Microbiol., 10, 10.3389/fmicb.2019.02603 · DOI
  63. Sousa, 2014, Pseudomonas aeruginosa diversification during infection development in cystic fibrosis lungs—a review., Pathogens, 3, 680, 10.3390/pathogens3030680 · DOI · Paper page
  64. Stewart, 2020, Risk factors for chronic biofilm-related infection associated with implanted medical devices., Clin. Microbiol. Infect., 26, 1034, 10.1016/j.cmi.2020.02.027 · DOI · Paper page
  65. Stewart, 2008, Physiological heterogeneity in biofilms., Nat. Rev. Microbiol., 6, 199, 10.1038/nrmicro1838 · DOI · Paper page
  66. Viducic, 2006, Functional analysis of spoT, relA and dksA genes on quinolone tolerance in Pseudomonas aeruginosa under nongrowing condition., Microbiol. Immunol., 50, 349, 10.1111/j.1348-0421.2006.tb03793.x · DOI
  67. Wang, 2019, Synergistic activity of fosfomycin, ciprofloxacin, and gentamicin against Escherichia coli and Pseudomonas aeruginosa biofilms., Front. Microbiol., 10, 10.3389/fmicb.2019.02522 · DOI
  68. Werner, 2004, Stratified growth in Pseudomonas aeruginosa biofilms., Appl. Environ. Microbiol., 70, 6188, 10.1128/AEM.70.10.6188-6196.2004 · DOI · Paper page
  69. Williamson, 2012, Heterogeneity in Pseudomonas aeruginosa biofilms includes expression of ribosome hibernation factors in the antibiotic-tolerant subpopulation and hypoxia-induced stress response in the metabolically active population., J. Bacteriol., 194, 2062, 10.1128/JB.00022-12 · DOI · Paper page
  70. Wiuff, 2005, Phenotypic tolerance: antibiotic enrichment of noninherited resistance in bacterial populations., Antimicrob. Agents Chemother., 49, 1483, 10.1128/AAC.49.4.1483-1494.2005 · DOI · Paper page
  71. Yu, 2012, In vitro evaluation of tobramycin and aztreonam versus Pseudomonas aeruginosa biofilms on cystic fibrosis-derived human airway epithelial cells., J. Antimicrob. Chemother., 67, 2673, 10.1093/jac/dks296 · DOI

Cited by

See all 113

Metadata

Authors
Soares, A., Alexandre, K., & Etienne, M.
Venue
Frontiers in Microbiology
Published
2020-08-27
Volume
11
ISSN
1664-302X
Cited by
113
References
7

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.